Zacks: Analysts Anticipate Inspire Medical Systems, Inc. (NYSE:INSP) to Post -$0.61 EPS

Wall Street analysts expect Inspire Medical Systems, Inc. (NYSE:INSP) to post earnings of ($0.61) per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Inspire Medical Systems’ earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.75). Inspire Medical Systems reported earnings of ($0.39) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 56.4%. The business is expected to issue its next quarterly earnings results after the market closes on Tuesday, November 2nd.

On average, analysts expect that Inspire Medical Systems will report full-year earnings of ($2.23) per share for the current year, with EPS estimates ranging from ($2.51) to ($1.92). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.51) per share, with EPS estimates ranging from ($2.32) to ($0.03). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Inspire Medical Systems.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Tuesday, August 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.13. Inspire Medical Systems had a negative net margin of 26.93% and a negative return on equity of 20.93%. The company had revenue of $52.96 million for the quarter, compared to analysts’ expectations of $44.90 million.

Several research analysts have recently commented on INSP shares. SVB Leerink lifted their price target on Inspire Medical Systems from $265.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, September 24th. Piper Sandler lifted their price target on Inspire Medical Systems from $215.00 to $238.00 and gave the stock an “overweight” rating in a report on Wednesday, August 4th. Zacks Investment Research upgraded Inspire Medical Systems from a “hold” rating to a “buy” rating and set a $263.00 price target on the stock in a report on Wednesday, October 6th. Finally, TheStreet upgraded Inspire Medical Systems from a “d” rating to a “c-” rating in a report on Monday, August 16th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $215.63.

NYSE INSP opened at $238.07 on Monday. Inspire Medical Systems has a 52 week low of $115.00 and a 52 week high of $264.40. The company has a quick ratio of 9.70, a current ratio of 10.25 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $226.40 and its 200-day simple moving average is $205.58. The firm has a market cap of $6.49 billion, a PE ratio of -136.04 and a beta of 1.61.

In related news, Director Georgia Melenikiotou sold 566 shares of the business’s stock in a transaction dated Friday, August 20th. The shares were sold at an average price of $212.22, for a total value of $120,116.52. Following the sale, the director now directly owns 566 shares in the company, valued at approximately $120,116.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.70% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of INSP. Macquarie Group Ltd. increased its stake in Inspire Medical Systems by 361.1% during the second quarter. Macquarie Group Ltd. now owns 309,905 shares of the company’s stock worth $59,892,000 after purchasing an additional 242,689 shares during the period. Principal Financial Group Inc. increased its stake in Inspire Medical Systems by 507.1% during the first quarter. Principal Financial Group Inc. now owns 265,834 shares of the company’s stock worth $55,025,000 after purchasing an additional 222,043 shares during the period. Balyasny Asset Management LLC increased its stake in Inspire Medical Systems by 2,154.4% during the second quarter. Balyasny Asset Management LLC now owns 174,893 shares of the company’s stock worth $33,800,000 after purchasing an additional 167,135 shares during the period. Marshall Wace North America L.P. increased its stake in Inspire Medical Systems by 40.8% during the second quarter. Marshall Wace North America L.P. now owns 455,063 shares of the company’s stock worth $87,946,000 after purchasing an additional 131,828 shares during the period. Finally, William Blair Investment Management LLC increased its stake in Inspire Medical Systems by 18.4% during the second quarter. William Blair Investment Management LLC now owns 761,475 shares of the company’s stock worth $147,163,000 after purchasing an additional 118,294 shares during the period. Institutional investors own 90.73% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead.

Read More: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.